VJOncology is committed to improving our service to you

GU Cancers 2019 | Nrf2 inhibitors to overcome chemoresistance

VJOncology is committed to improving our service to you

Simon Crabb

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, talks about targeting Nrf2 signaling pathways to overcome resistance to chemotherapeutic agents in bladder cancer. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics
Related videos
Chemo eligibility: bladder cancer
Srikala Sridhar
Penile cancer: avelumab
Srikala Sridhar
ATLAS update: rucaparib for bladder cancer
Petros Grivas
KRAS G12C target for urothelial carcinoma
Petros Grivas
Bladder: neoadjuvant immunotherapy & ctDNA
Petros Grivas
Bladder Cancer, Genitourinary Cancer
Cisplatin
GU Cancers 2019
Interview
15th February 2019
More from Simon Crabb
Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors
ProCAID: Investigating the use of AZD5363 alongside chemotherapy in mCRPC
Beyond cancer treatment: nurse specialists in the clinic
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals